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The 17 sustainable development goals adopted by 198 nations
in September 2015 provide a transformative framework for
global action across a wide range of areas. Health is an essential
component of many of the goals, such as those relating to
hunger, the environment, and education. The third goal (SDG3)
focuses explicitly on health: “Ensure healthy lives and promote
well-being for all at all ages.”1
Like health, trade is explicitly targeted in several of the goals.
However, it is also a critical determinant of other goals where
it has not been mentioned. We discuss the often overlooked
centrality of trade as a determinant of health through a case
study of antimicrobial resistance.2 Although not explicitly
mentioned in the sustainable development goals, antimicrobial
resistance threatens health, prosperity, and sustainable
development.3 It is responsible for an estimated 700 000 deaths
annually, forecast to be 10 million by 2050.3
Trade and health
The link between trade (agreements) and health (systems) has
been well documented over the past decade.4-8 The interaction
can be considered in four parts:
Commodities traded—This may be commodities harmful to
health, such as tobacco and alcohol,9 10 or those which may be
beneficial, such as fresh fruit and vegetables.11-13
Trade agreements and the provisions—The legal framework
provided for which goods can cross borders. Here the initial
focus was on access to medicines and intellectual property (and
this connection is explicitly acknowledged in SDG3 (target 3B),
mainly through the Agreement on Trade Related Aspects of
Intellectual Property Rights (TRIPS).14-16Over the past five years
the focus has been increasingly on regional and bilateral trade
agreements, often related to non-communicable diseases and
their risk factors.17-20
Trade in services21—This includes the movement of health
workers, telemedicine, medical tourism, and foreign direct
investment in health systems.22-24
Wider determinants of trade on health—These are both positive
and negative,25 including patterns of employment, urbanisation,
income, and housing, with considerable evidence to suggest
trade as determinant of health inequities.8-27
Trade and antimicrobial resistance
Antimicrobial resistance has rapidly ascended the political
agenda and is now recognised as a major threat to health,
prosperity, and global health security.28 Substantial
funding—with estimates of $40bn (£31bn; €35bn) over the next
10 years—is being sought to tackle the problem, and the World
Health Assembly endorsed a global action plan on antimicrobial
resistance in 2015.28 But meeting these challenges will not be
straightforward as it requires the collaboration of a large number
of stakeholders across animal, human, and environmental
spheres, often with conflicting interests and networks.29
Here we outline core areas where trade is critical to tackling
antimicrobial resistance, highlighting key areas for action to
achieve the SDGs and the 2030 agenda (box 1). We will focus
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mainly on commodities traded and the possible effect of trade
related regulation and agreements.
Trade and antimicrobial resistance intersect in several ways.
On a fundamental level trade (mobility) of people, animals, and
goods is connected to the spread of microbes, and in human
transmission there is a clear association with travel routes and
the emergence of antimicrobial resistance.5 30
Commodities
Trade in food products that contain resistant
bacteria
The most important sector in terms of trade relating to
antimicrobial resistance is in livestock, food animals, and their
feed, particularly in animals that host resistant bacteria. For
example, the global trade in meat is large: the United States
Department of Agriculture predicted that global production of
beef and veal would rise to 62 million tonnes in 2017, with
global exports predicted to be 9.6 million tonnes. Export of
broiler chicken meat was expected to be a record 11.2 million
tonnes.37
Drug resistant Escherichia coli can live on beef carcasses even
after 24 hours in a chiller and in minced beef that has been stored
for up to eight days.38 A study of raw meat samples provided
by retail traders in the Netherlands found meticillin resistant
Staphylococcus aureus (MRSA) inmany of the samples, ranging
from 35.3% of turkey samples to 2.2% of game samples.39While
many low and middle income countries export food products
and animals, their capacity to monitor antimicrobial resistance
adequately may be limited by overall budget constraints.35 40
Trade is a possible route for spreading resistance. One response,
where animals are tested for resistant strains as part of efforts
to control the spread of antimicrobial resistance, is likely to
affect trade immediately as animals with positive results would
be banned. A challenge here is that although many farmers are
advised to vaccinate their animals, it is hard to enforce and to
differentiate between livestock vaccinated and those infected.
Vaccination is also not currently routine in all countries. Thus,
national strategies to contain antimicrobial resistance through
vaccination may clash with global antimicrobial resistance
control and prevent farmers from trading their animals across
national borders.
Availability of antimicrobials
Trade in antimicrobials also affects their availability for human
and animal consumption. Part of the complexity of addressing
antimicrobial resistance is balancing access to medicines against
overconsumption; at the global level the consensus is that we
are probably consuming too many antimicrobials, but many of
the worlds’ poorest people still lack access to the essential
medicines they need. More than a million children die each year
from sepsis and untreated infection,31which is inconsistent with
target 8 of SDG3: “Achieving universal health coverage
including access to safe, effective, quality, and affordable
essential medicines for all.”
Clearly, efforts to tackle antimicrobial resistance have to
acknowledge that appropriate access is part of a wider global
trading system, which links incentives and profits from
medicines to volume of sales. Access to good quality
antimicrobials is determined by intellectual property provisions
set out as part of trade agreements, which set availability and
price within a country, as well as regulations concerning safety
and substandard medicines, relying on local action and
enforcement.
These intellectual property provisions are either insufficient or
insufficiently implemented to ensure access to all those who
require it. Here trade and the existing trade agreements,
including TRIPS, have a central role. Indeed, this is reflected
in one of the targets linked to SDG3, which calls for better use
of flexibilities granted under TRIPS to increase access to
medicines:
“Provide access to affordable essential medicines and vaccines,
in accordance with the Doha Declaration on the TRIPS
Agreement and Public Health, which affirms the right of
developing countries to use to the full the provisions in the
Agreement on Trade Related Aspects of Intellectual Property
Rights regarding flexibilities to protect public health, and, in
particular, provide access to medicines for all.”
Addressing antimicrobial resistance and maintaining drug
effectiveness while increasing access will be a key challenge
and require nuanced, equity sensitive policy implementation.
WHO’s recent reclassification of antimicrobials into “access”,
“watch”, and “reserve” marks a step in this direction.32
Trade also affects the availability of substandard “counterfeit”
antimicrobial drugs. Trade in counterfeit drugs is estimated to
run into billions.34 Availability of substandard antimicrobials is
likely to undermine attempts at public regulation of
antimicrobials, such as oversubscribing or the provision of
antimicrobials through informal providers. Little is known about
the effect of counterfeit trade in animal drugs.35 However, trade
agreements and greater regulation through bodies such as the
World Trade Organisation (WTO) offer solutions to this
challenge.
Trade agreements
The importance of trade and intellectual property provisions to
health and drug innovation is explicitly set out in target 3b of
SDG3. It is acknowledged as a core aspect of the Global Strategy
to Fight Antimicrobial Resistance and affirmed by the political
declaration resulting from the UN General Assembly special
session on antimicrobial resistance in 2016. The political
declaration calls on governments to: “recognise the importance
of delinking the cost of investment in research and development
on antimicrobial resistance from the price and volume of sales
so as to facilitate equitable and affordable access to new
medicines, diagnostic tools, vaccines.”
This is important as some of the largest unmet needs in the
research and development of new antimicrobials are found in
diseases such as tuberculosis, which contribute substantially to
the global antimicrobial resistance burden.33 New drugs that
would shorten the six month TB treatment course would
alleviate the huge burden on patients and health systems and
help to reduce the emergence of roughly 480 000 newmultidrug
resistant cases each year; these are at least partly related to poor
adherence to the long treatment course.33
However, research into TB treatment is not profitable enough
to warrant sufficient investment from drug companies. This is
reflected in the huge funding gap for TB; less than one third of
the $3.7bn for new drugs called for in the Stop TB Partnership’s
Global Plan to Stop TB 2011-15 was raised. Concerns extend
to diagnostic tools, vaccines for disease prevention, and wider
antimicrobial resistance related innovation. For example,
healthcare facilities may require new types of furniture and tools
with antibacterial surfaces. Such products may be an area of
future innovation but need to be affordable by low and middle
income countries.
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Box 1: Trade and health framework for antimicrobial resistance
Commodities traded
• Availability of antimicrobials
• Availability of food, including livestock, that may contain resistant bacteria
Trade agreements
• Regulation of counterfeit medicines
• Availability of new antimicrobials
• Interpretive labelling of food
Trade in services, including movement of people
• Spread of infection through human mobility
Effect on wider determinants of health
• Pattern of urbanisation
• Livestock farming practices
Food, animal, and plant safety in trade is regulated globally
through the WTO’s Sanitary and Phytosanitary Agreement. It
sets out basic standards of food safety based on science, while
providing some room for countries to set and retain their own
regulation. A recent analysis of interpretive nutrition labelling
and trade discussions under WTO regulation found that these
were often at odds and there was a risk that trade agreements
may constrain public health regulation.36
Trade in services
Other areas of trade and health also affect antimicrobial
resistance, even though these have had less attention. Trade in
services, including medical tourism, has been documented as
contributing to the spread of resistant bacteria.41
Wider determinants of health
Increases in global trade and the resulting changing patterns of
employment have resulted in intensive urbanisation and changes
in farming.5 These in turn affect resistance in animals and its
transmission. This also links closely to SDG11, which is focused
on urbanisation.
Discussion
Our case study highlights the need to consider trade when
seeking to tackle antimicrobial resistance and achieving the
sustainable development goals. Given the close connection
between food products, including food animals, and the spread
of antimicrobial resistance, this seems likely to become the
subject of future trade discussions and dispute—for example,
if individual countries wish to introduce public health regulation
that requires labelling of antibiotic use for food, or restrict
imports from specific countries.
Similar public health regulations around interpretive nutrition
labelling for food have led to trade discussions in the past, such
as regulation surrounding fatty cuts of meat in Ghana,42 or the
EU-US dispute on the use of growth hormone in cattle.43 It has
yet to be established whether antimicrobial resistance could be
used as a rationale for a “public health emergency” which allows
for greater flexibility around intellectual property regulation
under TRIPS.44.43
Regulation
It is therefore essential that trade agreements and regulating
bodies, such as the WTO and the World Intellectual Property
Organisation (WIPO), consider antimicrobial resistance in the
discussions on, and adjudication of disputes on, intellectual
property protection. Standard setting bodies such as the Codex
Alimentarius Commission and the OIE (World Organisation
for Animal Health) also have an important role since WTO
members are obliged to base regulations on relevant international
standards. By setting stronger regulations these bodies can help
tackle antimicrobial resistance and contribute to achieving the
sustainable development goals.
Free trade agreements are especially important because they
typically liberalise trade in agriculture to a greater extent than
WTO commitments and can include more specific obligations.
This relates closely to SDG16 (transparent institutions and
participatory policy processes).
Role of civil society, think tanks, and
academic institutions
It is important to develop international regulation and work with
national regulators to prevent pitching trade against public health
advocates in relation to antimicrobial resistance.45 46Civil society
has been active in highlighting the intersection between trade
and health, ranging from the HIV access movement to the recent
opposition to the TTIP agreement between the EU and the US.47
Involvement of civil society, think tanks, and academic
institutions is crucial for effective action on antimicrobial
resistance. In Sweden, which has responded to antimicrobial
resistance faster and earlier than other countries, public
mobilisation and non-governmental organisations such as ReAct
have been critical to placing the issue high on public and policy
agenda.48 Equally, recent protest by doctors and drug sellers in
Punjab, Pakistan, in response to stricter laws on substandard
drugs highlight the importance of involving civil society from
the outset and the need for greater public debate to improve
understanding of the challenges of antimicrobial resistance.
Advances are also needed in governance mechanisms to better
facilitate collaboration between health and trade, both in terms
of where health convenes, as well as where health needs to
engage for a better governance for health.25
These challenges throw down the gauntlet to think tanks and
academic institutions to go beyond knowledge generation and
dissemination. There is need to develop new ways of working
on health and trade to tackle the big issues in sustainable
development—such as the threat of antimicrobial resistance.
The myriad ways in which trade will affect sustainable
development also apply to sectors other than health. The lessons
for all sectors include the need to identify interlinkages between
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sectors and goals, the importance of governance, and the need
for strong and just institutions as well as inclusive processes.
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Key messages
Antimicrobial resistance shows how trade can affect health and the sustainable development goals
Trade and its intersection with health is critical to achieving sustainable development, yet it is little understood
Civil society, including think tanks, and academic institutions have a key role in exploring and acting on the intersection between trade
and health
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